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gery. It is clearly shown that dry eye disease worsens following the cataract surgery in patients with prior history of ocular surface
disease, Also new cases of dry eye might appear. Current strategies for the timely diagnosis and proper management of dry eye
syndrome in the face of cataract surgery patients are mainly emphasized. To achieve the best outcome in cataract surgery, a
healthy ocular surface is crucial. While ocular surface preparation is indispensable in patients with established ocular surface dis-
ease, it is also helpful in those with minimal signs or symptoms of surface disease. The current approach begins with early diagnosis
and drastic management of ocular surface disease before cataract surgery using a stepwise regimen customized to each patient
and disease severity. These measures are continued throughout and after the surgery.
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Several risk factors have been proposed for dry eye syn-
drome; among them older age, female gender, diabetes
and high blood pressure are known for quite some time. In
general ocular surface disease is more common in the
elderly1,2 and since age-related cataract comprises most of
cataract surgeries, the identification and management of ocu-
lar surface disease is therefore imperative in majority of
patients undergoing cataract surgery. According to long-term
population-based studies the incidence rates of dry eye
among individuals between ages 43 and 86 years at 5 and
10 years of follow-up are 13.3% and 21.6% respectively.3,4
It has also been shown that both incidence and severity of
dry eye symptoms increase even further after cataract sur-
gery.5 In particular, the reduction in tear meniscus height
and tear break up time6 and squamous metaplasia in
conjunctival impression cytology7 is documented afterphacoemulsification. To assess dry eye and meibomian gland
dysfunction after cataract surgery, Han et al.8 followed 48
patients after phacoemulsification. The ocular symptoms
got worse at 1 month and 3 months postoperatively. More-
over lid margin abnormal examination was significantly
increased and TBUT decreased postoperatively. Yet, meib-
ography score, SPK, lower tear meniscus height, depth, and
area and ST did not change significantly 1 or 3 months after
cataract surgery.
The exacerbation of ocular surface disease after cataract
surgery is possibly multifactorial: In one hand transection of
the corneal nerves and damage to corneal epithelium from
exposure to microscopic light and intense irrigation of the
tear film during operation and on the other, elevation of
inflammatory factors in the tear film due to ocular surface irri-
tation and use of topical anesthesia during surgery in addition
to preservative containing topical eye drops administered
after surgery.9e:
al.com
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surface disease are also at higher risk of post-operative com-
plications such as infections and corneal melts. Conse-
quently, an assertive approach in the management of the
ocular surface disease is imperative in many cataract surgery
patients. This article reviews the latest approaches for the
diagnosis and management of ocular surface disease in the
setting of cataract surgery. Roberts CW, Carniglia PE, Brazzo BG, Comparison of topical cyclosporine, punctal
occlusion, and a combination for the treatment of dry eye. Cornea 2007;26:805–809.Identification of patients with ocular surface disease
Detection of ocular surface disease prior to cataract sur-
gery provides an opportunity to improve the surface health
before proceeding with surgery. History constitutes a crucial
element in the diagnosis of patients with dry eyes or ‘‘dysfunc-
tional tear syndrome’’.10 Besides grittiness or discomfort,
blurry vision that is worsened by visual activity, may some-
times be ignored as a symptom of dry eye and could be falsely
attributed to the cataract symptoms.11 Fluctuating vision
either before or after cataract surgery is a sign of tear film
insufficiency in most patients. Similarly, history of systemic
collagen vascular diseases, arthritis or dry mouth provides
important clues for the associated ocular surface diseases.
Clinical examination may be helpful in finding further clues.
Debris in the tear film, a low tear meniscus height, lid margin
abnormalities, reduced meibomian gland expression and con-
junctival inflammation are examples of such findings.
The most commonly performed tests include Schirmer’s test
(ST), tear film break-up time (TBUT), and ocular surface staining.
Interestingly, despite their central role in detection and grading
the severity of surface disease, clinical findings and diagnostic
tests are only weakly associatedwith patient symptoms inocular
surface disease.12 It is suggested to perform ST without anes-
thesia with the eyes closed for 2 or 5 min.13 ST is a practical test
to detect patients with moderate to severe aqueous tear
deficiency. An abnormal TBUT is similarly suggestive of an
inadequate tear film and is a valuable diagnostic test when
looking for ocular surface disease pre-operatively.
Ocular surface staining with fluorescein is a widely used
diagnostic modality to assess the severity of the dry eyes.
Rose Bengal staining can detect mucous deficiency and is
more sensitive than fluorescein in detecting early signs of
tear film insufficiency. To identify patients with high risk
of developing dry eye signs and symptoms after phacoe-
mulsification. Patients are examined after one hour from
instillation of dailating and anesthetic drops. Any punctate
keratopathy warns problems in maintaining a healthy epi-
thelial surface after surgery.14 Neurotrophic corneal disease
is relatively common especially in diabetic patients and is a
frequent cause of chronic surface disease. While a neuro-
trophic patient’s complaints of the typical dry eye symp-
toms are minimal, they are specifically at higher risk for
ocular surface complications following cataract surgery.
Corneal sensation can be tested using a cotton wisp to
identify patients with neurotrophic keratopathy.15 Jiang
et al. have used a new method called Noninvasive Kerato-
graph assessment of tear film break-up time which demon-
strates a color-coded tear break-up map, that might enable
surgeons to more efficiently assess TBUT preoperatively;
however, there is no data showing the efficacy of using
such technology in the reduction of dry eye after cataract
surgery.16Optimizing ocular surface prior to the surgery
A cataract surgery candidate who has poorly controlled
ocular surface disease, surgery could typically wait until the
surface can be optimized. Delphi approach to treatment
recommendations for DED was published in 2006.17
The management of dry eye commonly begins with artifi-
cial tears. Artificial tear is shown to alleviate the symptoms,
improve vision as well as dry eye signs (TBUT) in the majority
of cataract surgery patients.18
Topical steroids and immunoregulatory agents are the
main choices in moderate to severe dry eye currently in
use. Numerous studies have shown the efficacy of topical cor-
ticosteroids in treatment of dry eyes.19 The most beneficial
effect of steroids is the rapid onset of action and making
them very handy in circumstances that immediate response
is intended. In a randomized, double-masked, placebo-
controlled study in keratoconjunctivitis sicca patients, lote-
prednol etabonate ophthalmic suspension 0.5%-treated
group had significantly better outcomes than vehicle-treated
group after 2 weeks of therapy.20
Cyclosporine’s popularity is due to the lack of steroid
induced side effects for a long-term use. Although, in order
to reach therapeutic levels several weeks of treatment are
necessary and for an unknown reason some patients do not
benefit this topical medication even with a long-term use.21
The mechanism of action of cyclosporine in tear production
increase is not fully understood. The increase in the number
of conjunctival goblet cells has been shown22; in addition,
immunomodulatory effects of the medication reduce inflam-
mation in most cases. Many studies23–26 have reported the
beneficial effects of topical cyclosporine therapy twice daily
for at least 6 months in improvement of signs and symptoms
of dry eye disease.
Donnenfeld et al.25 showed that cyclosporine therapy
improves visual quality after multifocal intraocular lens
implantation signifying its beneficial effect on tear-film qual-
ity. Decreasing the dosage of topical 0.05% cyclosporine to
once daily for at least a year, may have equal effects in dry
eye syndrome.26
Given that the inflammation is increased significantly after
cataract surgery, it is crucially important to suppress the
inflammation pre-operatively.
In patients with significant aqueous deficiency, punctual
occlusion might be considered. This modality of treatment
is preferably performed after controlling the ocular surface
inflammation. Combination of punctual occlusion and cyclo-
sporine is shown to improve ST scores, rose Bengal staining,
and reduction in overall artificial tear use compared to either
treatments alone.,27
Management of lid disease is necessary for the best surgi-
cal outcomes. Blepharitis is the most frequent cause of cata-
ract surgery cancellation28 since it seems to be a primary risk
factor for endophthalmitis.29
The basic step in pre-operative care in patients with lid
margin disease is a prolonged commitment to eyelid
hygiene. Topical antibiotics such as topical azithromycin are
choice in unresponsive patients.30 In severe blepharitis or in
the presence of complications such as phlyctenules or severe
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used for short periods of time. Systemic doxycycline or min-
ocycline, are the last resort for refractory cases most of whom
have significant meibomian gland disease or ocular rosa-
cea.31 Tetracyclines improve the symptoms and TBUT and
are typically started at least one month before cataract sur-
gery. Increasing intake of Omega-3 fatty acids32 may also
have anti-inflammatory effects and are shown to decrease
signs and symptoms of dry eye and may also be beneficial
in the management of lid disease.33Intra-operative measures to minimize surface
damage
The ocular surface is prone to damage from dryness dur-
ing the surgery as well as preservative containing eye drops.
Inordinate instilment and wrong use of preservative contain-
ing eye drops are significant factors that lead to the develop-
ment of dry eye after phacoemulsification and corneal
toxicity.8
Frequent irrigations with BSS or the use of viscous eye
lubricants or viscoelastics can minimize the desiccating stress
to the surface.34
The surgical incision may affect the ocular surface after
cataract surgery.35 Even small incision cataract wounds may
create localized damage to the corneal nerves with subse-
quent reduced corneal sensation.
As shown in a prospective study, the use of aspirating
speculum was found to worsen dry eye-related parameters,
such as conjunctival staining, TBUT, conjunctivochalasis
grades, and OSDI, during the early postoperative period.
Though these parameters returned to baseline at 1 month
after the operation.36
In a recently, published article about the incidence and
pattern of dry eyes post cataract surgery, Kasetsuwan et al.
suggested that using light filters, decreasing exposure time,
proper irrigation, and soft manipulation of the ocular surface
tissue may reduce the complications after surgery.37Post-operative management to optimize the result
of cataract surgery
After cataract surgery the signs and symptoms of ocular
surface disease typically worsen.
Dry eye symptoms can develop instantly after phacoemul-
sification. The severity can peak on day seven but both symp-
toms and signs may ameliorate over time.37 Prolonged use of
eye drops may be an important contributing factor.
Consequently, in patients with surface disease it is preferred
to stop or taper medications when no longer needed. Topical
NSAIDs such as nepafenac, ketorolac and diclofenac have
been reported to cause corneal melting mainly in the pres-
ence of epithelial breakdown.38,39 These complications are
more likely to occur in patients with significant ocular surface
disease such as Sjogren’s syndrome. The concomitant use of
topical steroids with NSAIDs may reduce this complication
however, it does not completely prevent it. Therefore, in
patients with severe ocular surface disease it is wise to mini-
mize or even avoid the use of topical NSAIDs especially as a
single agent. In a recent paper, using 0.05% cyclosporine
twice daily, Chung et al. showed a significant increase in
TBUT and ST-I in patients after cataract surgery while theseindices were shown to be abnormal postoperatively.40 Some
prefer to pretreat patients using topical steroid for few
months prior to starting cyclosporine to decrease
discomfort.41
Another remarkable complication is sterile corneal melts
which has been reported in patients with immune mediated
ocular surface diseases such as Sjogren’s syndrome, graft
versus host disease, and Stevens-Johnson syndrome.42,43
Optimization of the ocular surface prior to cataract surgery
is imperative in these patients. While topical steroids are cau-
tiously used in patients with an unstable surface, systemic
immunosuppression may be indicated to overpower inflam-
mation in the setting of systemic disease. Cataract surgery
in patients with ocular mucous membrane pemphigoid
(MMP) requires controlling the disease for a minimum of
one year. Systemic steroids are highly recommended prior
to cataract surgery in these patients.
In conclusion, given that cataract surgery is a surface dam-
aging event, it is important to consider ocular surface in
patients pre-operatively. It has clearly been shown to worsen
ocular surface disease at least temporarily. Ocular surface
preparation is beneficial not only in patients with established
ocular surface disease, but also in those with minimal signs or
symptoms of surface disease. Currently, there is more interest
among the cataract surgeons to further improve the out-
comes of surgery by aggressively treating the ocular surface
before and after operation. This is especially important in
patients with moderate to severe ocular surface diseases
which are at increased risk for complications, most notably
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